No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 21 of the 40 quarters in the window, leaving 19 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 71.5x · 10Y median 34.0x · 71st percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:02.877Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Insight Molecular Diagnostics Inc. (IMDX) stock was $3.70 as of Oct 6, 2026, 9:59 AM EDT, up 0.82% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +9.5% · 3-year avg +5.2%/yr · 5-year avg -44.4%/yr
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories.
Medical - Diagnostics & Research · Nashville, TN
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.24
Revenue Est.
$235120.00
Last Quarter Results
EPS
$-0.24
vs Estimate
$-0.23
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1IMDX | $119.47M | $3.70 | +0.82% | +9.50% | -44.39% | -29.11% | N/A |
| 2CRBU | $118.02M | $1.19 | +0.00% | -47.42% | -44.43% | N/A | vs IMDX |
| 3HURA | $121.00M | $1.90 | +1.60% | -27.96% | -45.49% | -52.09% | vs IMDX |
| 4GNLX | $116.36M | $2.60 | -0.19% | -41.42% | N/A | N/A | vs IMDX |
| 5ENGN | $122.59M | $1.83 | -2.14% | -75.71% | N/A | N/A | vs IMDX |
| 6LENZ | $116.25M | $3.71 | +3.28% | -92.54% | -35.49% | N/A | vs IMDX |
forward FY estimate
N/A
$239000.00
vs Estimate
$352500.00
Consensus Rating
Based on 4 analysts
Average Price Target
$8.25
+123.0% upside
Low
$4.00
Current
$3.70
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.26 | $-0.24 | $-0.21 | 2 |
| Quarter ending Dec 2026 | $-0.24 | $-0.23 | $-0.22 | 2 |
| Quarter ending Mar 2027 | $-0.66 | $-0.24 | $0.01 | 1 |
| Quarter ending Jun 2027 | $-0.61 | $-0.22 | $0.01 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.91 | $-0.90 | $-0.90 | 3 |
| FY 2027 | $-0.90 | $-0.86 | $-0.82 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $96250.00 | $235120.00 | $288750.00 | 5 |
| Quarter ending Dec 2026 | $98640.00 | $467280.00 | $1.09M | 5 |
| Quarter ending Mar 2027 | $74664.00 | $353700.00 | $821307.00 | 4 |
| Quarter ending Jun 2027 | $186914.00 | $885450.00 | $2.06M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $401166.00 | $962800.00 | $1.70M | 5 |
| FY 2027 | $1.00M | $6.67M | $11.91M | 5 |
